Maternal and child life years gained by transfusing low titer group O whole blood in trauma: A computer simulation
Transfusion · 2024
DOI: 10.1111/trf.17767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2024. Verfasst von Mark H Yazer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: ABO Blood-Group System, Computer Simulation, Wounds and Injuries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences, AABB Foundation.
Abstract (Originalsprache)
Background
Using low titer group O whole blood (LTOWB) is increasingly popular for resuscitating trauma patients. LTOWB is often RhD‐positive, which might cause D‐alloimmunization and hemolytic disease of the fetus and newborn (HDFN) if transfused to RhD‐negative females of childbearing potential (FCP). This simulation determined the number of life years gained by the FCP and her future children if she was resuscitated with LTOWB compared with conventional component therapy (CCT).
Methods
The model simulated 500,000 injured FCPs of each age between 0 and 49 years with LTOWB mortality relative reductions (MRRs) compared with components between 0.1% and 25%. For each surviving FCP, number of life years gained was calculated using her age at injury and average life expectancy for American women. The number of expected future pregnancies for FCPs that did not survive was also based on her age at injury; each future child was assigned the maximum lifespan unless they suffered perinatal mortality or serious neurological events from HDFN.
Results
The LTOWB group with an MRR 25% compared with CCT had the largest total life years gained. The point of equivalence for RhD‐positive LTOWB compared to CCT, where life years lost due to severe HDFN was equivalent to life years gained due to FCP survival/future childbearing, occurred at an MRR of approximately 0.1%.
Conclusion
In this model, RhD‐positive LTOWB resulted in substantial gains in maternal and child life years compared with CCT. A >0.1% relative mortality reduction from LTOWB offset the life years lost to HDFN mortality and severe neurological events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Trauma and Transfusion Medicine Research Center, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of Obstetrics and Gynecology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
ORCID-Profile: Mark H Yazer, Christine Leeper, Philip C Spinella, Sarah Horvath, Jansen N Seheult
Förderung
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
- AABB Foundation
Zitieren
APA
Yazer, M. H., Leeper, C., Spinella, P. C., Emery, S. P., Horvath, S., & Seheult, J. N. (2024). Maternal and child life years gained by transfusing low titer group O whole blood in trauma: A computer simulation. Transfusion. https://doi.org/10.1111/trf.17767
Vancouver
Yazer MH, Leeper C, Spinella PC, Emery SP, Horvath S, Seheult JN. Maternal and child life years gained by transfusing low titer group O whole blood in trauma: A computer simulation. Transfusion. 2024. doi:10.1111/trf.17767
BibTeX
@article{Yazer2024,
author = {Yazer, Mark H and Leeper, Christine and Spinella, Philip C and Emery, Stephen P and Horvath, Sarah and Seheult, Jansen N},
title = {Maternal and child life years gained by transfusing low titer group O whole blood in trauma: A computer simulation},
journal = {Transfusion},
year = {2024},
doi = {10.1111/trf.17767}
}
EUVIMED